普芦卡必利治疗慢性特发性便秘的疗效：伴有中至重度腹胀患者的分析。
Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating.
机构信息
Massachusetts General Hospital, Boston, Massachusetts, USA.
Takeda Development Centre Americas, Inc., Lexington, Massachusetts, USA.
出版信息
Am J Gastroenterol. 2022 Jan 1;117(1):184-188. doi: 10.14309/ajg.0000000000001521.
INTRODUCTION
This post hoc analysis evaluated the effect of prucalopride on abdominal bloating in participants with chronic idiopathic constipation (CIC) who had moderate to very severe bloating at baseline.
METHODS
Data from 6 phase 3/4 studies of prucalopride in participants with CIC were pooled. Abdominal bloating was assessed weekly using a 5-point scale (0-4).
RESULTS
The proportion of bloating responders (≥1-point improvement in abdominal bloating score at week 12) was higher in participants treated with prucalopride (62.1%) vs placebo (49.6%).
DISCUSSION
The prucalopride arm had a higher proportion of bloating responders vs placebo in this study population.
简介
本事后分析评估了普芦卡必利对基线时存在中重度腹胀的慢性特发性便秘（CIC）患者的腹胀的影响。
方法
汇总了普芦卡必利治疗 CIC 参与者的 6 项 3/4 期研究的数据。使用 5 分制（0-4）每周评估一次腹胀。
结果
在第 12 周时，腹胀改善≥1 分的腹胀缓解者比例在普芦卡必利治疗组（62.1%）高于安慰剂组（49.6%）。
讨论
在该研究人群中，普芦卡必利组的腹胀缓解者比例高于安慰剂组。
Zotero 插件